Quanterix opened lower at $2.98, compared with its previous close of $3.02. In the last trading session, the stock traded between $2.86 and $3.10. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Quanterix is now worth
$ 5.23
Resulting in a loss of
$ 94.77 (94.77%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.15 (-5.07%)
Day High
$3.10
Day Low
$2.86
Day Open
$2.98
Prev Close
$3.02
Volume
5,53,837
1W Return
-5.22%
1M Return
-9.04%
3M Return
9.34%
6M Return
2.39%
1Y Return
-42.66%
Market Cap ($ Mn)
136
PE Ratio
-
PB Ratio
0.53
PEG Ratio
-
ROE
-34.58%
ROCE
-34.35%
EPS (TTM)
$-0.46
1 Week
-5.22%
1 Month
-9.04%
3 Months
9.34%
6 Months
2.39%
9 Months
-52.06%
Quanterix Q3FY26 Results: Revenue $35M up 6.3% QoQ, loss narrows
Total revenue of $35 million, up 6.3% sequentially but down 13.1% YoY. Net loss narrowed to $21.6 million, an improvement of $11.9 million YoY. Florida Medicaid approved Alzheimer’s blood biomarker testing at $480 per test. Lucent AD test sales doubled sequentially driven by new partnerships. Full-year 2026 revenue guidance narrowed to $142–$146 million.
3 days agoQuanterix grants RSUs to new CCO under Nasdaq rule
Quanterix granted 260,315 RSUs to new CCO James Gute. Two other employees received an aggregate of 365,326 RSUs. Awards vest over four years subject to continued employment. Grants approved under Nasdaq Listing Rule 5635(c)(4).
1mo agoQuanterix Q2 adjusted EPS misses estimates, sales rise 34%
Quanterix reported Q2 adjusted EPS of $(0.47), missing estimates by 2.17%, while sales grew 34.44% YoY to $32.906M but missed consensus. The loss per share was unchanged from the prior year.
3mo agoQuanterix grants 141,820 RSUs to new CFO Jason Faessler
Quanterix Corporation granted 141,820 RSUs to new CFO Jason Faessler on July 15, 2026. The RSUs vest annually over four years, subject to continued employment. The grant was made under the 2025 Inducement Plan per Nasdaq rules.
3mo agoAnthem covers Quanterix blood test for Alzheimer's
Quanterix Corporation announced that Anthem Blue Cross and Blue Shield will cover its LucentAD Complete blood test for Alzheimer’s disease starting July 1, 2026, benefiting approximately 40 million members. A new peer-reviewed study confirms the test's diagnostic parity with mass spectrometry and shows it reduces diagnostic ambiguity by three-fold. Additionally, data presented at AAIC 2026 demonstrated the test's ability to identify preclinical Alzheimer’s disease in a community screening study.
4mo agoQuanterix stock rises 5.28% on CFO vesting, leadership change
Quanterix Corp. shares increased 5.28% in pre-market trading to $3.39 after SEC filings showed outgoing CFO Vandana Sriram vested 1,833 RSUs and incoming CFO Jason Faessler started his role. The stock is trading near the lower end of its 52-week range.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Quanterix is now worth
$ 5.23
Resulting in a loss of
$ 94.77 (94.77%)
Note: Past profits do not guarantee future returns.
